Literature DB >> 16020257

Competitive quenching: a possible novel approach in protecting RPE cells from damage during PDT.

Dov Weinberger1, Yonina Ron, Moshe Lusky, Dan Gaaton, Arie Orenstein, Michael Blank, Mathilda Mandel, Tamar Livnat, Tilda Barliya, Gad Lavie.   

Abstract

PURPOSE: The purpose of this study is to demonstrate feasibility of using our novel concept, termed competitive quenching, for protecting the choroidal extravascular compartment and retinal pigment epithelium (RPE) from verteporfin (VP)-induced phototoxicity using hypericin. Furthermore, we aim to achieve partitioning of the quencher, hypericin, in the extravascular space and VP within the microvascular compartment of the chorio-retinal complex in vivo.
METHODS: We protect RPE cells from damage inflicted by photoactivated VP by introducing hypericin into these cells prior to photosensitization to quench the photosensitizing activity of VP. Cell protection levels were measured by MTT and Hemacolor viability assays. Wavelength range used for VP photoexcitation (700 +/- 40 nm) excludes the absorption range of hypericin, preventing the latter from photoactivation. Pharmacokinetic conditions, in which hypericin spreads throughout the choroidal and retinal extravascular space while VP is confined to the vasculature, are delineated using double-fluorescence imaging.
RESULTS: Cell viability increased 3- to 5-fold when 10-20 microM hypericin were present in RPE cells during photosensitization with 0.1-0.5 microM VP. VP fluorescence intensity was unchanged by the presence of hypericin in the cells. Hypericin administered intravenously to rats was confined to the choroidal vasculature after 15 min to 2 hr. Subsequently, hypericin partitioned to the choroidal and retinal extravascular space. VP administered at this time was confined to the microvasculature.
CONCLUSIONS: RPE and choroid may potentially be protected by compartmentalizing hypericin to the extravascular compartment while VP administered shortly before photosensitization is confined to the microvasculature. Adverse photodynamic therapy (PDT) damage to choroidal tissues adjacent to neovasculature targeted for photoablation have the potential of being prevented by competitive quenching with hypericin.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16020257     DOI: 10.1080/02713680590927597

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  4 in total

1.  Phototoxicity in human retinal pigment epithelial cells promoted by hypericin, a component of St. John's wort.

Authors:  Albert R Wielgus; Colin F Chignell; David S Miller; Ben Van Houten; Joel Meyer; Dan-Ning Hu; Joan E Roberts
Journal:  Photochem Photobiol       Date:  2007 May-Jun       Impact factor: 3.421

Review 2.  Verteporfin: a review of its use in the management of subfoveal choroidal neovascularisation.

Authors:  Caroline Fenton; Caroline M Perry
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

3.  Clinical efficacy of intravitreal ranibizumab in early and mid-idiopathic choroidal neovascularization.

Authors:  Chuanfeng Fan; Qiang Ji; Yu Wang; Xiangwen Shu; Juan Xie
Journal:  J Ophthalmol       Date:  2014-04-27       Impact factor: 1.909

4.  Impact of methylenetetrahydrofolate reductase C677T polymorphism on the efficacy of photodynamic therapy in patients with neovascular age-related macular degeneration.

Authors:  Francesco Parmeggiani; Carla Enrica Gallenga; Ciro Costagliola; Francesco Semeraro; Mario R Romano; Roberto Dell'Omo; Andrea Russo; Katia De Nadai; Donato Gemmati; Sergio D'Angelo; Elena Bolletta; Francesco Saverio Sorrentino
Journal:  Sci Rep       Date:  2019-02-22       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.